Drug recalls (page 3)
748 recalls.
- AMINAOCAPROIC ACID INJECTION recall (American Regent, Inc.)
DrugClass IIReported August 26, 2026 · Presence of Particulate Matter: Product contaminated with particulate matter identified as hair, glass and/or paraformaldehyde - Cyanocobalamin injection USP recall (American Regent, Inc.)
DrugClass IIReported August 26, 2026 · Presence of Particulate Matter: Product contaminated with particulate matter identified as hair, glass and/or paraformaldehyde - Cyanocobalamin injection USP recall (American Regent, Inc.)
DrugClass IIReported August 26, 2026 · Presence of Particulate Matter: Product contaminated with particulate matter identified as hair, glass and/or paraformaldehyde - Nitroglycerin injection recall (American Regent, Inc.)
DrugClass IIReported August 26, 2026 · Presence of Particulate Matter: Product contaminated with particulate matter identified as hair, glass and/or paraformaldehyde - Morphine Sulfate Injection recall (Fresenius Kabi USA, LLC)
DrugClass IReported August 26, 2026 · Labeling: Label Mixup: MicroVault labeled as Morphine 2 mg/1 mL, contains a Prefilled Syringe of Dilaudid 0.5 mg/0.5 mL. - Acamprosate Calcium recall (Mylan Pharmaceuticals Inc)
DrugClass IIReported August 26, 2026 · Failed Dissolution Specifications - Carbamazepine Tablets recall (Golden State Medical Supply Inc.)
DrugClass IIReported August 26, 2026 · CGMP deviations: tablets with black specks. - Carbamazepine Tablets recall (SUN PHARMACEUTICAL INDUSTRIES INC)
DrugClass IIReported August 26, 2026 · CGMP Deviations; black spots found on tablets from burnt excipient during manufacturing - Libtayo recall (Regeneron Pharmaceuticals Inc)
DrugClass IIReported August 26, 2026 · Lack of Assurance of Sterility - PEMRYDI RTU recall (Shilpa Medicare Limited)
DrugClass IIReported August 26, 2026 · Discolored solution. The firm has received market complaints reporting green to dark green discoloration in certain vials - PEMRYDI RTU recall (Shilpa Medicare Limited)
DrugClass IIReported August 26, 2026 · Discolored solution. The firm has received market complaints reporting green to dark green discoloration in certain vials - Cefazolin in Dextrose recall (Baxter Healthcare Corporation)
DrugClass IReported August 19, 2026 · Presence of Particulate Matter - Optiray Imaging Bulk Package-350 recall (Liebel-Flarsheim Company LLC)
DrugClass IReported August 19, 2026 · Presence of Particulate Matter: comprising polyethylene and other plastic materials, stainless steel and glass. - Glutathione recall (Victory Medical Center Pharmacy)
DrugClass IReported August 19, 2026 · Microbial Contamination of Sterile Products - out of specifications results were obtained for bacterial endotoxin. - Kian Pee Wan Capsules recall (Buy-Herbal)
DrugClass IReported August 19, 2026 · Marketed Without an Approved NDA/ANDA: Product contains undeclared drug ingredients dexamethasone and cyproheptadine. - CLINDAMYCIN PALMITATE HYDROCHLORIDE FOR ORAL SOLUTION recall (Heritage Pharmaceuticals Inc)
DrugClass IIReported August 19, 2026 · Presence of Foreign Substance: presence of particles and white flakes in the reconstituted bottles. - CLEAR EYES Maximum Itchy Eye Relief recall (Prestige Brands Holdings)
DrugClass IIReported August 19, 2026 · Lack of assurance of sterility. The recall is due to potential contamination - SILDENAFIL CITRATE USP recall (Shoolin Pharma Chem LLP)
DrugClass IIReported August 19, 2026 · CGMP Deviations:Noted during FDA inspection - TADALAFIL USP recall (Shoolin Pharma Chem LLP)
DrugClass IIReported August 19, 2026 · CGMP Deviations:Noted during FDA inspection - TADALAFIL USP recall (Shoolin Pharma Chem LLP)
DrugClass IIReported August 19, 2026 · CGMP Deviations:Noted during FDA inspection - TADALAFIL USP recall (Shoolin Pharma Chem LLP)
DrugClass IIReported August 19, 2026 · CGMP Deviations:Noted during FDA inspection - SILDENAFIL CITRATE USP recall (Shoolin Pharma Chem LLP)
DrugClass IIReported August 19, 2026 · CGMP Deviations:Noted during FDA inspection - SEMAGLUTIDE 20mg recall (Apollo Care, LLC)
DrugClass IIReported August 19, 2026 · Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material - SEMAGLUTIDE 10mg recall (Apollo Care, LLC)
DrugClass IIReported August 19, 2026 · Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material - SEMAGLUTIDE 7.5mg recall (Apollo Care, LLC)
DrugClass IIReported August 19, 2026 · Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material - SEMAGLUTIDE 5mg recall (Apollo Care, LLC)
DrugClass IIReported August 19, 2026 · Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material - SEMAGLUTIDE 2.5mg recall (Apollo Care, LLC)
DrugClass IIReported August 19, 2026 · Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material - SEMAGLUTIDE 0.9mg recall (Apollo Care, LLC)
DrugClass IIReported August 19, 2026 · Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material - SEMAGLUTIDE 9mg recall (Apollo Care, LLC)
DrugClass IIReported August 19, 2026 · Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material - SEMAGLUTIDE 4.5mg recall (Apollo Care, LLC)
DrugClass IIReported August 19, 2026 · Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material - SEMAGLUTIDE 6.75mg recall (Apollo Care, LLC)
DrugClass IIReported August 19, 2026 · Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material - SEMAGLUTIDE 2.25MG recall (Apollo Care, LLC)
DrugClass IIReported August 19, 2026 · Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material - SEMAGLUTIDE 12.5MG recall (Apollo Care, LLC)
DrugClass IIReported August 19, 2026 · Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material - Diovan recall (Novartis Pharmaceuticals Corporation)
DrugClass IIReported August 19, 2026 · Failed Dissolution Specifications - Mirabegron Extended-Release Tablets recall (Zydus Pharmaceuticals (USA) Inc)
DrugClass IIReported August 12, 2026 · CGMP: Due to Out of Specification (OOS) result for N-Nitroso Mirabegron impurity. - Cyclophosphamide for Injection recall (Sunny Pharmtech Inc.)
DrugClass IReported August 12, 2026 · Presence of Particulate Matter; identified as stainless steel - Cyclophosphamide for Injection recall (Sunny Pharmtech Inc.)
DrugClass IReported August 12, 2026 · Presence of Particulate Matter; identified as stainless steel - Total Parental Nutrition - Pediatric PN Patient-Specific TPN Bag recall (Central Admixture Pharmacy Services Inc)
DrugClass IIIReported August 12, 2026 · Incorrect Product Formulation - Dicyclomine Hydrochloride Capsules recall (Aurobindo Pharma USA Inc)
DrugClass IIReported August 12, 2026 · shortfill; reports of empty capsules. - Dabigatran Etexilate Capsules recall (Ascend Laboratories, LLC)
DrugClass IIIReported August 5, 2026 · Failed impurity/degradation specification: an OOS result observed in Related substance test analysis w.r.t Impurity II, Impurity III and Total impurities for... - Dabigatran Etexilate Capsules recall (Ascend Laboratories, LLC)
DrugClass IIIReported August 5, 2026 · Failed impurity/degradation specification: an OOS result observed in Related substance test analysis w.r.t Impurity II, Impurity III and Total impurities for... - Dabigatran Etexilate Capsules recall (Ascend Laboratories, LLC)
DrugClass IIIReported August 5, 2026 · Failed impurity/degradation specification: an OOS result observed in Related substance test analysis w.r.t Impurity II, Impurity III and Total impurities for... - Mycophenolate Mofetil for Injection USP recall (MYLAN PHARMACEUTICALS INC)
DrugClass IIReported August 5, 2026 · Presence of precipitate - Azelaic Acid Gel recall (Glenmark Pharmaceuticals Inc., USA)
DrugClass IIReported August 5, 2026 · CGMP Deviations: Product quality complaints concerning abnormal texture or consistency (described as grainy, gritty, or sandy) were received. - Dorzolamide HCl and Timolol Maleate Ophthalmic Solution recall (MICRO LABS USA INC)
DrugClass IIReported August 5, 2026 · Defective Container: Firm received multiple complaints of broken cap spikes and undeliverable drops. - Trokendi XR recall (Supernus Pharmaceuticals, Inc.)
DrugClass IIIReported July 29, 2026 · Failed Dissolution Specifications - Divalproex Sodium Delayed-Release Tablets recall (Bionpharma Inc.)
DrugClass IIReported July 29, 2026 · Presence of Foreign Tablets/Capsules - Glycopyrrolate Oral Solution recall (Precision Dose Inc.)
DrugClass IIReported July 29, 2026 · Failed Impurities/Degradation Specifications - Dabigatran etexilate Capsules recall (Ascend Laboratories, LLC)
DrugClass IIIReported July 29, 2026 · Failed Impurities/Degradation Specifications: OOS result was observed during the related substance test analysis with respect to Impurity II, Impurity III and... - Dabigatran etexilate Capsules recall (Ascend Laboratories, LLC)
DrugClass IIIReported July 29, 2026 · Failed Impurities/Degradation Specifications: OOS result was observed during the related substance test analysis with respect to Impurity II, Impurity III and... - Cetirizine Hydrochloride Tablets USP 5 mg recall (JB Chemicals and Pharmaceuticals Ltd)
DrugClass IReported July 29, 2026 · Cross Contamination with Other Products: Customer complaints for appearance of discolored tablets and red dots observed on Cetirizine Hydrochloride Tablets... - Xylocaine recall (Fresenius Kabi USA, LLC)
DrugClass IIReported July 29, 2026 · Presence of Particulate Matter: Hair was found in products - Xylocaine recall (Fresenius Kabi USA, LLC)
DrugClass IIReported July 29, 2026 · Presence of Particulate Matter: Hair was found in products - Naropin recall (Fresenius Kabi USA, LLC)
DrugClass IIReported July 29, 2026 · Presence of Particulate Matter: Hair was found in products - Lidocaine HCl Injection recall (Fresenius Kabi USA, LLC)
DrugClass IIReported July 29, 2026 · Presence of Particulate Matter: Hair was found in products - Glycopyrrolate Injection recall (Fresenius Kabi USA, LLC)
DrugClass IIReported July 29, 2026 · Presence of Particulate Matter: Hair was found in product - Rising recall (Rising Pharma Holding, Inc.)
DrugClass IIReported July 29, 2026 · Presence of Precipitate: medication was crystallizing and particles floating in the bottle - Rohto Cooling Eye Drops Cool Relief recall (Rohto-Mentholatum (Vietnam) Co., Ltd.)
DrugClass IIReported July 29, 2026 · Lack of Assurance of Sterility - Rohto Cooling Eye Drops Dry Aid recall (Rohto-Mentholatum (Vietnam) Co., Ltd.)
DrugClass IIReported July 29, 2026 · Lack of Assurance of Sterility - Rohto Cooling Eye Drops Dry Aid recall (Rohto-Mentholatum (Vietnam) Co., Ltd.)
DrugClass IIReported July 29, 2026 · Lack of Assurance of Sterility - Rohto Cooling Eye Drops Digi Eye recall (Rohto-Mentholatum (Vietnam) Co., Ltd.)
DrugClass IIReported July 29, 2026 · Lack of Assurance of Sterility - Rohto Cooling Eye Drops Optic Glow recall (Rohto-Mentholatum (Vietnam) Co., Ltd.)
DrugClass IIReported July 29, 2026 · Lack of Assurance of Sterility - Rohto Cooling Eye Drops Max Strength recall (Rohto-Mentholatum (Vietnam) Co., Ltd.)
DrugClass IIReported July 29, 2026 · Lack of Assurance of Sterility - Rohto Cooling Eye Drops Max Strength recall (Rohto-Mentholatum (Vietnam) Co., Ltd.)
DrugClass IIReported July 29, 2026 · Lack of Assurance of Sterility - Rohto Cooling Eye Drops ALL-IN-ONE recall (Rohto-Mentholatum (Vietnam) Co., Ltd.)
DrugClass IIReported July 29, 2026 · Lack of Assurance of Sterility - Lidolog Kit recall (Asclemed USA Inc.)
DrugClass IIIReported July 29, 2026 · Labeling: Not Elsewhere Classified: The label wrap covers the barcode, making it hard to scan - Amlodipine and Olmesartan Medoxomil Tablets recall (Ascend Laboratories, LLC)
DrugClass IIReported July 29, 2026 · Failed Dissolution Specifications; Olmesartan Medoxomil content below specifications - Levothyroxine Sodium Tablets recall (Major Pharmaceuticals)
DrugClass IIReported July 29, 2026 · Subpotent Drug - Levothyroxine Sodium Tablets recall (Major Pharmaceuticals)
DrugClass IIReported July 29, 2026 · Subpotent Drug - Levothyroxine Sodium Tablets recall (Major Pharmaceuticals)
DrugClass IIReported July 29, 2026 · Subpotent Drug - Levothyroxine Sodium Tablets recall (Major Pharmaceuticals)
DrugClass IIReported July 29, 2026 · Subpotent Drug - Levothyroxine Sodium Tablets recall (Major Pharmaceuticals)
DrugClass IIReported July 29, 2026 · Subpotent Drug - Levothyroxine Sodium Tablets recall (Major Pharmaceuticals)
DrugClass IIReported July 29, 2026 · Subpotent Drug - Levothyroxine Sodium Tablets recall (Major Pharmaceuticals)
DrugClass IIReported July 29, 2026 · Subpotent Drug - Levothyroxine Sodium Tablets recall (Major Pharmaceuticals)
DrugClass IIReported July 29, 2026 · Subpotent Drug - Levothyroxine Sodium Tablets recall (Major Pharmaceuticals)
DrugClass IIReported July 29, 2026 · Subpotent Drug - Levothyroxine Sodium Tablets recall (Major Pharmaceuticals)
DrugClass IIReported July 29, 2026 · Subpotent Drug - Levothyroxine Sodium Tablets recall (Major Pharmaceuticals)
DrugClass IIReported July 29, 2026 · Subpotent Drug - Levothyroxine Sodium Tablets recall (Major Pharmaceuticals)
DrugClass IIReported July 29, 2026 · Subpotent Drug - BD ChloraPrep Clear recall (CareFusion 213, LLC)
DrugClass IIReported July 22, 2026 · Lack of Assurance of Sterility: Affected product may exhibit an open or incomplete seal on the packaging of the applicator - CLEVIPREX recall (Chiesi USA, Inc.)
DrugClass IIReported July 22, 2026 · Lack of Assurance of Sterility - CAREone recall (Bell Pharmaceuticals, Inc)
DrugClass IIReported July 22, 2026 · SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%). - meijer recall (Bell Pharmaceuticals, Inc)
DrugClass IIReported July 22, 2026 · SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%). - Foster & Thrive recall (Bell Pharmaceuticals, Inc)
DrugClass IIReported July 22, 2026 · SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%). - LEADER recall (Bell Pharmaceuticals, Inc)
DrugClass IIReported July 22, 2026 · SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%). - GOOD NEIGHBOR PHARMACY recall (Bell Pharmaceuticals, Inc)
DrugClass IIReported July 22, 2026 · SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%). - FAMILY Wellness recall (Bell Pharmaceuticals, Inc)
DrugClass IIReported July 22, 2026 · SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%). - AUDIOLOGIST'S CHOICE recall (Bell Pharmaceuticals, Inc)
DrugClass IIReported July 22, 2026 · SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%). - TopCare Health recall (Bell Pharmaceuticals, Inc)
DrugClass IIReported July 22, 2026 · SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%). - QC Quality Choice recall (Bell Pharmaceuticals, Inc)
DrugClass IIReported July 22, 2026 · SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%). - Clinere recall (Bell Pharmaceuticals, Inc)
DrugClass IIReported July 22, 2026 · SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%). - CVS Health recall (Bell Pharmaceuticals, Inc)
DrugClass IIReported July 22, 2026 · SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%). - Nystatin Cream USP recall (Padagis US LLC)
DrugClass IIReported July 22, 2026 · Subpotent Drug: Low out of specification assay results performed during long-term stability testing. - Clomiphene Citrate USP Active Pharmaceutical Ingredient recall (Shimoga Chemicals)
DrugClass IIReported July 15, 2026 · cGMP deviations - Azacitidine for Injection 100mg/Vial recall (Reliance Life Sciences Private Limited)
DrugClass IIReported July 15, 2026 · Lack of Sterility Assurance - Bortezomib for Injection 3.5mg/Vial recall (Reliance Life Sciences Private Limited)
DrugClass IIReported July 15, 2026 · Lack of Sterility Assurance - Pemetrexed for Injection 500mg/Vial recall (Reliance Life Sciences Private Limited)
DrugClass IIReported July 15, 2026 · Lack of Sterility Assurance - Pemetrexed for Injection 100mg/Vial recall (Reliance Life Sciences Private Limited)
DrugClass IIReported July 15, 2026 · Lack of Sterility Assurance - Drogueria San Juan Puerto Rico Isopropyl Alcohol 70% recall (Gasco Industrial Corp.)
DrugClass IIReported July 15, 2026 · Subpotent drug - Drogueria San Juan Puerto Rico Isopropyl Alcohol 70% recall (Gasco Industrial Corp.)
DrugClass IIReported July 15, 2026 · Subpotent drug